In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Cyclophosphamide
/ administration & dosage
Disease-Free Survival
Doxorubicin
/ administration & dosage
Female
Gene Expression Regulation, Neoplastic
HIV Infections
/ drug therapy
HIV-1
/ metabolism
Humans
Lymphoma, Large B-Cell, Diffuse
/ drug therapy
Male
Middle Aged
Prednisone
/ administration & dosage
Proto-Oncogene Proteins c-bcl-2
/ biosynthesis
Rituximab
/ administration & dosage
Survival Rate
Vincristine
/ administration & dosage
BCL2 expression
HIV
diffuse large B-cell lymphoma
non-Hodgkin’s lymphoma
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
16
05
2019
accepted:
04
07
2019
pubmed:
31
8
2019
medline:
29
7
2020
entrez:
31
8
2019
Statut:
ppublish
Résumé
The prognostic value of cell of origin (COO) classification and BCL2 expression is not well established in diffuse large B-cell lymphoma (DLBCL) patients with human immunodeficiency virus (HIV) infection in the recent era. Phenotypic patterns were determined by immunohistochemistry (IHC) of pathological samples from patients with HIV-associated DLBCL prospectively enrolled in the French AIDS and Viral Hepatitis CO16 Lymphovir cohort between 2008 and 2015. Molecular subgroup classification into germinal centre B-cell (GCB) and non-GCB subtypes was determined using the Hans algorithm. Among 52 samples of systemic DLBCL subjected to centralized pathological analysis, 25 of the 42 tested for BCL2 expression were positive. Samples were further classified into GCB (n = 19) and non-GCB (n = 16) subtypes and 17 remained unclassified. In multivariable analysis, BCL2 expression was an independent pejorative prognostic biomarker [4-year progression-free survival (PFS): 52% for BCL2
Substances chimiques
BCL2 protein, human
0
Proto-Oncogene Proteins c-bcl-2
0
R-CHOP protocol
0
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
413-423Subventions
Organisme : INSERM Agence Nationale de Recherche sur le Sida et les Hépatites
Pays : International
Informations de copyright
© 2019 British Society for Haematology and John Wiley & Sons Ltd.
Références
Achenbach, C.J., Cole, S.R., Kitahata, M.M., Casper, C., Willig, J.H., Mugavero, M.J. & Saag, M.S. (2011) Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS, 25, 691-700.
Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson, J., Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, Timothy C., Weisenburger, D.D., Armitage, J.O., Warnke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O. & Staudt, L.M. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503-511.
Antinori, A., Cingolani, A., Alba, L., Ammassari, A., Serraino, D., Ciancio, B.C., Palmieri, F., De Luca, A., Larocca, L.M., Ruco, L., Ippolito, G. & Cauda, R. (2001) Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS, 15, 1483-1491.
Barrans, S.L., Evans, P.A.S., O'Connor, S.J.M., Kendall, S.J., Owen, R.G., Haynes, A.P., Morgan, G.J. & Jack, A.S. (2003) The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clinical Cancer Research, 9, 2133-2139.
Barta, S.K., Lee, J.Y., Kaplan, L.D., Noy, A. & Sparano, J.A. (2012) Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer, 118, 3977-3983.
Batlle-López, A., González de Villambrosía, S., Francisco, M., Malatxeberria, S., Sáez, A., Montalban, C., Sánchez, L., Garcia, J., González-Barca, E., López-Hernández, A., Ruiz-Marcellan, M.C., Mollejo, M., Grande, C., Richards, K.L., Hsi, E.D., Tzankov, A., Visco, C., Xu-Monette, Z.Y., Cao, X., Young, K.H., Piris, M.A., Conde, E. & Montes-Moreno, S. (2016) Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. Oncotarget, 7, 18036-18049.
Berglund, M., Thunberg, U., Amini, R.-M., Book, M., Roos, G., Erlanson, M., Linderoth, J., Dictor, M., Jerkeman, M., Cavallin-Ståhl, E., Sundström, C., Rehn-Eriksson, S., Backlin, C., Hagberg, H., Rosenquist, R. & Enblad, G. (2005) Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Modern Pathology, 18, 1113-1120.
Besson, C., Goubar, A., Gabarre, J., Rozenbaum, W., Pialoux, G., Châtelet, F.P., Katlama, C., Charlotte, F., Dupont, B., Brousse, N., Huerre, M., Mikol, J., Camparo, P., Mokhtari, K., Tulliez, M., Salmon-Céron, D., Boué, F., Costagliola, D. & Raphaël, M. (2001) Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood, 98, 2339-2344.
Besson, C., Lancar, R., Prevot, S., Algarte-Genin, M., Delobel, P., Bonnet, F., Meyohas, M.-C., Partisani, M., Oberic, L., Gabarre, J., Goujard, C., Boue, F., Coppo, P., Costello, R., Hendel-Chavez, H., Mekerri, N., Dos Santos, G., Recher, C., Delarue, R., Casasnovas, R.-O., Taoufik, Y., Mounier, N. & Costagliola, D. (2017) Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. AIDS, 31, 2493-2501.
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Bohlius, J., Schmidlin, K., Costagliola, D., Fätkenheuer, G., May, M., Caro-Murillo, A.M., Mocroft, A., Bonnet, F., Clifford, G., Karafoulidou, A., Miro, J.M., Lundgren, J., Chene, G. & Egger, M. (2009) Incidence and risk factors of HIV-related non-Hodgkin’s lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antiviral Therapy, 14, 1065-1074.
Bonnet, F., Burty, C., Lewden, C., Costagliola, D., May, T., Bouteloup, V., Rosenthal, E., Jougla, E., Cacoub, P., Salmon, D., Chêne, G. & Morlat, P.; Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group & Mortavic Study Group. (2009) Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clinical Infectious Diseases, 48, 633-639.
Boué, F., Gabarre, J., Gisselbrecht, C., Reynes, J., Cheret, A., Bonnet, F., Billaud, E., Raphael, M., Lancar, R. & Costagliola, D. (2006) Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 24, 4123-4128.
Campo, E., Swerdlow, S.H., Harris, N.L., Pileri, S., Stein, H. & Jaffe, E.S. (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood, 117, 5019-5032.
Carbone, A. & Gloghini, A. (2005) AIDS-related lymphomas: from pathogenesis to pathology. British Journal of Haematology, 130, 662-670.
Chadburn, A., Chiu, A., Lee, J.Y., Chen, X., Hyjek, E., Banham, A.H., Noy, A., Kaplan, L.D., Sparano, J.A., Bhatia, K. & Cesarman, E. (2009) Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. Journal of Clinical Oncology, 27, 5039-5048.
Chao, C., Silverberg, M.J., Martínez-Maza, O., Chi, M., Abrams, D.I., Haque, R., Zha, H.D., McGuire, M., Xu, L. & Said, J. (2012) Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma. Clinical Cancer Research, 18, 4702-4712.
Choi, W.W.L., Weisenburger, D.D., Greiner, T.C., Piris, M.A., Banham, A.H., Delabie, J., Braziel, R.M., Geng, H., Iqbal, J., Lenz, G., Vose, J.M., Hans, C.P., Fu, K., Smith, L.M., Li, M., Liu, Z., Gascoyne, R.D., Rosenwald, A., Ott, G., Rimsza, L.M., Campo, E., Jaffe, E.S., Jaye, D.L., Staudt, L.M. & Chan, W.C. (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clinical Cancer Research, 15, 5494-5502.
Coiffier, B. (2001) Diffuse large cell lymphoma. Current Opinion in Oncology, 13, 325-334.
Coutinho, R., Pria, A.D., Gandhi, S., Bailey, K., Fields, P., Cwynarski, K., Wilson, A., Papanastasopoulos, P., Tenant-Flowers, M., Webb, A., Burns, F., Marcus, R.E., Orkin, C., Montoto, S. & Bower, M. (2014) HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. AIDS, 28, 689-697.
Cox, D.R. (1972) Regression models and life tables. Journal of the Royal Statistical Society: Series B (Methodological), 34, 187-220.
Dal Maso, L. & Franceschi, S. (2003) Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. The Lancet. Oncology, 4, 110-119.
Davids, M.S., Roberts, A.W., Anderson, M.A., Pagel, J.M., Kahl, B.S., Gerecitano, J.F., Darden, D.E., Nolan, C.E., Gressick, L.A., Yang, J., Chyla, B.J., Busman, T.A., Graham, A.M., Cerri, E., Enschede, S.H., Humerickhouse, R.A. & Seymour, J.F. (2012) The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study. Blood, 120, 304-304.
Dunleavy, K. & Wilson, W.H. (2010) Role of molecular subtype in predicting outcome of AIDS-related diffuse large B-cell lymphoma. Journal of Clinical Oncology, 28, e260; author reply e261-262.
Dunleavy, K., Little, R.F., Pittaluga, S., Grant, N., Wayne, A.S., Carrasquillo, J.A., Steinberg, S.M., Yarchoan, R., Jaffe, E.S. & Wilson, W.H. (2010) The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood, 115, 3017-3024.
Engels, E.A., Pfeiffer, R.M., Goedert, J.J., Virgo, P., McNeel, T.S., Scoppa, S.M. & Biggar, R.J.; HIV/AIDS Cancer Match Study (2006) Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS, 20, 1645-1654.
Engels, E.A., Biggar, R.J., Hall, H.I., Cross, H., Crutchfield, A., Finch, J.L., Grigg, R., Hylton, T., Pawlish, K.S., McNeel, T.S. & Goedert, J.J. (2008) Cancer risk in people infected with human immunodeficiency virus in the United States. International Journal of Cancer, 123, 187-194.
Franceschi, S., Lise, M., Clifford, G.M., Rickenbach, M., Levi, F., Maspoli, M., Bouchardy, C., Dehler, S., Jundt, G., Ess, S., Bordoni, A., Konzelmann, I., Frick, H., Dal Maso, L., Elzi, L., Furrer, H., Calmy, A., Cavassini, M., Ledergerber, B., Keiser, O., Swiss HIV Cohort Study. (2010) Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. British Journal of Cancer, 103, 416-422.
Gerecitano, J.F., Roberts, A.W., Seymour, J.F., Wierda, W.G., Kahl, B.S., Pagel, J.M., Puvvada, S., Kipps, T.J., Anderson, M.A., Dunbar, M., Zhu, M., Gressick, L., Wagner, L., Kim, S.Y., Enschende, S.H., Humerickhouse, R.A. & Davids, M.S. (2015) A Phase 1 study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma. Blood, 126, 254-254.
Gibson, T.M., Morton, L.M., Shiels, M.S., Clarke, C.A. & Engels, E.A. (2014) Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS, 28, 2313-2318.
Gopal, S., Patel, M.R., Yanik, E.L., Cole, S.R., Achenbach, C.J., Napravnik, S., Burkholder, G.A., Reid, E.G., Rodriguez, B., Deeks, S.G., Mayer, K.H., Moore, R.D., Kitahata, M.M., Eron, J.J. & Richards, K.L. (2013) Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. Journal of the National Cancer Institute, 105, 1221-1229.
Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Müller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-282.
Hentrich, M. & Barta, S. (2016) HIV-associated Hematological Malignancies. Springer International Publishing, Switzerland.
Herida, M., Mary-Krause, M., Kaphan, R., Cadranel, J., Poizot-Martin, I., Rabaud, C., Plaisance, N., Tissot-Dupont, H., Boue, F., Lang, J.-M. & Costagliola, D. (2003) Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. Journal of Clinical Oncology, 21, 3447-3453.
Hermine, O., Haioun, C., Lepage, E., d’Agay, M.F., Briere, J., Lavignac, C., Fillet, G., Salles, G., Marolleau, J.P., Diebold, J., Reyas, F. & Gaulard, P. (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood, 87, 265-272.
Hleyhel, M., Belot, A., Bouvier, A.-M., Tattevin, P., Pacanowski, J., Genet, P., De Castro, N., Berger, J.-L., Dupont, C., Lavolé, A., Pradier, C., Salmon, D., Simon, A., Martinez, V., Spano, J.-P., Costagliola, D. & Grabar, S.; FHDH-ANRS CO4. (2015) Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. results from the FHDH-ANRS CO4 cohort. International Journal of Cancer, 137, 2443-2453.
Hoffmann, C., Wolf, E., Fätkenheuer, G., Buhk, T., Stoehr, A., Plettenberg, A., Stellbrink, H.-J., Jaeger, H., Siebert, U. & Horst, H.-A. (2003) Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS, 17, 1521-1529.
Hoffmann, C., Tiemann, M., Schrader, C., Janssen, D., Wolf, E., Vierbuchen, M., Parwaresch, R., Ernestus, K., Plettenberg, A., Stoehr, A., Fatkenheuer, G., Wyen, C., Oette, M. & Horst, H.-A. (2005) AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood, 106, 1762-1769.
Horn, H., Ziepert, M., Becher, C., Barth, T.F.E., Bernd, H.-W., Feller, A.C., Klapper, W., Hummel, M., Stein, H., Hansmann, M.-L., Schmelter, C., Möller, P., Cogliatti, S., Pfreundschuh, M., Schmitz, N., Trümper, L., Siebert, R., Loeffler, M., Rosenwald, A., Ott, G.; German High-Grade Non-Hodgkin Lymphoma Study Group. (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood, 121, 2253-2263.
Howe, J.G. & Steitz, J.A. (1986) Localization of Epstein-Barr virus-encoded small RNAs by in situ hybridization. Proceedings of the National Academy of Sciences of the United States of America, 83, 9006-9010.
Hu, S., Xu-Monette, Z.Y., Tzankov, A., Green, T., Wu, L., Balasubramanyam, A., Liu, W., Visco, C., Li, Y., Miranda, R.N., Montes-Moreno, S., Dybkaer, K., Chiu, A., Orazi, A., Zu, Y., Bhagat, G., Richards, K.L., Hsi, E.D., Choi, W.W.L., Zhao, X., van Krieken, J.H., Huang, Q., Huh, J., Ai, W., Ponzoni, M., Ferreri, A.J.M., Zhou, F., Slack, G.W., Gascoyne, R.D., Tu, M., Variakojis, D., Chen, W., Go, R.S., Piris, M.A., Moller, M.B., Medeiros, L.J. & Young, K.H. (2013) MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood, 121, 4021-4031; quiz 4250.
Iqbal, J., Sanger, W.G., Horsman, D.E., Rosenwald, A., Pickering, D.L., Dave, B., Dave, S., Xiao, L., Cao, K., Zhu, Q., Sherman, S., Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Ott, G., Müller-Hermelink, H.K., Delabie, J., Braziel, R.M., Jaffe, E.S., Campo, E., Lynch, J.C., Connors, J.M., Vose, J.M., Armitage, J.O., Grogan, T.M., Staudt, L.M. & Chan, W.C. (2004) BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. The American Journal of Pathology, 165, 159-166.
Johnson, N.A., Slack, G.W., Savage, K.J., Connors, J.M., Ben-Neriah, S., Rogic, S., Scott, D.W., Tan, K.L., Steidl, C., Sehn, L.H., Chan, W.C., Iqbal, J., Meyer, P.N., Lenz, G., Wright, G., Rimsza, L.M., Valentino, C., Brunhoeber, P., Grogan, T.M., Braziel, R.M., Cook, J.R., Tubbs, R.R., Weisenburger, D.D., Campo, E., Rosenwald, A., Ott, G., Delabie, J., Holcroft, C., Jaffe, E.S., Staudt, L.M. & Gascoyne, R.D. (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Journal of Clinical Oncology, 30, 3452-3459.
Kaplan, E. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statistical Association, 53, 457-481.
Kaplan, L.D., Lee, J.Y., Ambinder, R.F., Sparano, J.A., Cesarman, E., Chadburn, A., Levine, A.M. & Scadden, D.T. (2005) Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood, 106, 1538-1543.
Klanova, M., Andera, L., Brazina, J., Svadlenka, J., Benesova, S., Soukup, J., Prukova, D., Vejmelkova, D., Jaksa, R., Helman, K., Vockova, P., Lateckova, L., Molinsky, J., Maswabi, B.C.L., Alam, M., Kodet, R., Pytlik, R., Trneny, M. & Klener, P. (2016) Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Clinical Cancer Research, 22, 1138-1149.
Lanoy, E., Spano, J.-P., Bonnet, F., Guiguet, M., Boué, F., Cadranel, J., Carcelain, G., Couderc, L.-J., Frange, P., Girard, P.-M., Oksenhendler, E., Poizot-Martin, I., Semaille, C., Agut, H., Katlama, C. & Costagliola, D.; ONCOVIH study group. (2011) The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. International Journal of Cancer, 129, 467-475.
Laurent, C., Baron, M., Amara, N., Haioun, C., Dandoit, M., Maynadié, M., Parrens, M., Vergier, B., Copie-Bergman, C., Fabiani, B., Traverse-Glehen, A., Brousse, N., Copin, M.-C., Tas, P., Petrella, T., Rousselet, M.-C., Brière, J., Charlotte, F., Chassagne-Clement, C., Rousset, T., Xerri, L., Moreau, A., Martin, A., Damotte, D., Dartigues, P., Soubeyran, I., Peoch, M., Dechelotte, P., Michiels, J.F., de Mascarel, A., Berger, F., Bossard, C., Arbion, F., Quintin-Roué, I., Picquenot, J.M., Patey, M., Fabre, B., Sevestre, H., Le Naoures, C., Chenard-Neu, M.P., Bastien, C., Thiebault, S., Martin, L., Delage, M., Filleron, T., Salles, G., Molina, T.J., Delsol, G., Brousset, P. & Gaulard, P. (2017) Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network. Journal of Clinical Oncology, 35, 2008-2017.
Lenz, G., Wright, G.W., Emre, N.C.T., Kohlhammer, H., Dave, S.S., Davis, R.E., Carty, S., Lam, L.T., Shaffer, A.L., Xiao, W., Powell, J., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Gascoyne, R.D., Connors, J.M., Campo, E., Jaffe, E.S., Delabie, J., Smeland, E.B., Rimsza, L.M., Fisher, R.I., Weisenburger, D.D., Chan, W.C. & Staudt, L.M. (2008a) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proceedings of the National Academy of Sciences of the United States of America, 105, 13520-13525.
Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., Vose, J., Bast, M., Fu, K., Weisenburger, D.D., Greiner, T.C., Armitage, J.O., Kyle, A., May, L., Gascoyne, R.D., Connors, J.M., Troen, G., Holte, H., Kvaloy, S., Dierickx, D., Verhoef, G., Delabie, J., Smeland, Eb, Jares, P., Martinez, A., Lopez-Guillermo, A., Montserrat, E., Campo, E., Braziel, R.M., Miller, T.P., Rimsza, L.M., Cook, J.R., Pohlman, B., Sweetenham, J., Tubbs, R.R., Fisher, R.I., Hartmann, E., Rosenwald, A., Ott, G., Muller-Hermelink, H.-K., Wrench, D., Lister, T.A., Jaffe, E.S., Wilson, W.H., Chan, W.C. & Staudt, L.M.; Lymphoma/Leukemia Molecular Profiling Project. (2008b) Stromal gene signatures in large-B-cell lymphomas. The New England Journal of Medicine, 359, 2313-2323.
Little, R.F., Pittaluga, S., Grant, N., Steinberg, S.M., Kavlick, M.F., Mitsuya, H., Franchini, G., Gutierrez, M., Raffeld, M., Jaffe, E.S., Shearer, G., Yarchoan, R. & Wilson, W.H. (2003) Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood, 101, 4653-4659.
Maso, L.D., Suligoi, B., Franceschi, S., Braga, C., Buzzoni, C., Polesel, J., Zucchetto, A., Piselli, P., Falcini, F., Caldarella, A., Zanetti, R., Vercelli, M., Guzzinati, S., Russo, A., Tagliabue, G., Iachetta, F., Ferretti, S., Limina, R.M., Mangone, L., Michiara, M., Stracci, F., Pirino, D.R., Piffer, S., Giacomin, A., Vitarelli, S., Mazzoleni, G., Iannelli, A., Contrino, M.L., Fusco, M., Tumino, R., Fanetti, A.C., De Paoli, P., Decarli, A. & Serraino, D.; Cancer and AIDS Registries Linkage Study. (2014) Survival after cancer in Italian persons with AIDS, 1986-2005: a population-based estimation. Journal of Acquired Immune Deficiency Syndromes (1999), 66, 428-435.
Montoto, S., Wilson, J., Shaw, K., Heath, M., Wilson, A., McNamara, C., Orkin, C., Nelson, M., Johnson, M., Bower, M. & Cwynarski, K. (2010) Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt’s lymphoma. AIDS, 24, 851-856.
Mounier, N., Spina, M., Gabarre, J., Raphael, M., Rizzardini, G., Golfier, J.-B., Vaccher, E., Carbone, A., Coiffier, B., Chichino, G., Bosly, A., Tirelli, U. & Gisselbrecht, C. (2006) AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood, 107, 3832-3840.
Nyman, H., Adde, M., Karjalainen-Lindsberg, M.-L., Taskinen, M., Berglund, M., Amini, R.-M., Blomqvist, C., Enblad, G. & Leppä, S. (2007) Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood, 109, 4930-4935.
Oriol, A., Ribera, J.-M., Bergua, J., Giménez Mesa, E., Grande, C., Esteve, J., Brunet, S., Moreno, M.-J., Escoda, L., Hernandez-Rivas, J.-M. & Hoelzer, D. (2008) High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer, 113, 117-125.
Ota, Y., Hishima, T., Mochizuki, M., Kodama, Y., Moritani, S., Oyaizu, N., Mine, S., Ajisawa, A., Tanuma, J., Uehira, T., Hagiwara, S., Yajima, K., Koizumi, Y., Shirasaka, T., Kojima, Y., Nagai, H., Yokomaku, Y., Shiozawa, Y., Koibuchi, T., Iwamoto, A., Oka, S., Hasegawa, H., Okada, S. & Katano, H. (2014) Classification of AIDS-related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition. Cancer Medicine, 3, 143-153.
Ribera, J.-M., Oriol, A., Morgades, M., González-Barca, E., Miralles, P., López-Guillermo, A., Gardella, S., López, A., Abella, E. & García, M.; PETHEMA, GELTAMO, GELCAB and GESIDA Groups. (2008) Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. British Journal of Haematology, 140, 411-419.
Robbins, H.A., Pfeiffer, R.M., Shiels, M.S., Li, J., Hall, H.I. & Engels, E.A. (2015) Excess cancers among HIV-infected people in the United States. Journal of the National Cancer Institute, 107, April 2015, dju503. https://doi.org/10.1093/jnci/dju503
Roberts, A.W., Davids, M.S., Pagel, J.M., Kahl, B.S., Puvvada, S.D., Gerecitano, J.F., Kipps, T.J., Anderson, M.A., Brown, J.R., Gressick, L., Wong, S., Dunbar, M., Zhu, M., Desai, M.B., Cerri, E., Heitner Enschede, S., Humerickhouse, R.A., Wierda, W.G. & Seymour, J.F. (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. The New England Journal of Medicine, 374, 311-322.
Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Yang, L., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Powell, J., Duffey, P.L., Longo, D.L., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Montserrat, E., López-Guillermo, A., Grogan, T.M., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T. & Staudt, L.M.; Lymphoma/Leukemia Molecular Pro. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. The New England Journal of Medicine, 346, 1937-1947.
Savage, K.J., Monti, S., Kutok, J.L., Cattoretti, G., Neuberg, D., De Leval, L., Kurtin, P., Dal Cin, P., Ladd, C., Feuerhake, F., Aguiar, R.C.T., Li, S., Salles, G., Berger, F., Jing, W., Pinkus, G.S., Habermann, T., Dalla-Favera, R., Harris, N.L., Aster, J.C., Golub, T.R. & Shipp, M.A. (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood, 102, 3871-3879.
Scott, D.W., Mottok, A., Ennishi, D., Wright, G.W., Farinha, P., Ben-Neriah, S., Kridel, R., Barry, G.S., Hother, C., Abrisqueta, P., Boyle, M., Meissner, B., Telenius, A., Savage, K.J., Sehn, L.H., Slack, G.W., Steidl, C., Staudt, L.M., Connors, J.M., Rimsza, L.M. & Gascoyne, R.D. (2015) Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. Journal of Clinical Oncology, 33, 2848-2856.
Shiels, M.S., Pfeiffer, R.M., Gail, M.H., Hall, H.I., Li, J., Chaturvedi, A.K., Bhatia, K., Uldrick, T.S., Yarchoan, R., Goedert, J.J. & Engels, E.A. (2011) Cancer burden in the HIV-infected population in the United States. Journal of the National Cancer Institute, 103, 753-762.
Simard, E.P. & Engels, E.A. (2010) Cancer as a cause of death among people with AIDS in the United States. Clinical Infectious Diseases, 51, 957-962.
Sparano, J.A., Lee, J.Y., Kaplan, L.D., Levine, A.M., Ramos, J.C., Ambinder, R.F., Wachsman, W., Aboulafia, D., Noy, A., Henry, D.H., Von Roenn, J., Dezube, B.J., Remick, S.C., Shah, M.H., Leichman, L., Ratner, L., Cesarman, E., Chadburn, A. & Mitsuyasu, R. & AIDS Malignancy Consortium. (2010) Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood, 115, 3008-3016.
Stilgenbauer, S., Eichhorst, B., Schetelig, J., Coutre, S., Seymour, J.F., Munir, T., Puvvada, S.D., Wendtner, C.-M., Roberts, A.W., Jurczak, W., Mulligan, S.P., Böttcher, S., Mobasher, M., Zhu, M., Desai, M., Chyla, B., Verdugo, M., Enschede, S.H., Cerri, E., Humerickhouse, R., Gordon, G., Hallek, M. & Wierda, W.G. (2016) Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. The Lancet Oncology, 17, 768-778.
Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G.A., Zelenetz, A.D. & Jaffe, E.S. (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127, 2375-2390.
Tsuyama, N., Sakata, S., Baba, S., Mishima, Y., Nishimura, N., Ueda, K., Yokoyama, M., Terui, Y., Hatake, K., Kitagawa, M., Ishizuka, N., Tomita, N. & Takeuchi, K. (2017) BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. Blood, 130, 489-500.
Uldrick, T.S., Ison, G., Rudek, M.A., Noy, A., Schwartz, K., Bruinooge, S., Schenkel, C., Miller, B., Dunleavy, K., Wang, J., Zeldis, J. & Little, R.F. (2017) Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group. Journal of Clinical Oncology, 35, 3774-3780.
Vandenhende, M.-A., Roussillon, C., Henard, S., Morlat, P., Oksenhendler, E., Aumaitre, H., Georget, A., May, T., Rosenthal, E., Salmon, D., Cacoub, P., Costagliola, D., Chêne, G. & Bonnet, F.; ANRS EN20 Mortalité 2010 Study Group. (2015) Cancer-related causes of death among HIV-INFECTED PATIENTS in France in 2010: evolution since 2000. PLoS ONE, 10, e0129550.
Visco, C., Li, Y., Xu-Monette, Z.Y., Miranda, R.N., Green, T.M., Li, Y., Tzankov, A., Wen, W., Liu, W.M., Kahl, B.S., d'Amore, E.S., Montes-Moreno, S., Dybkaer, K., Chiu, A., Tam, W., Orazi, A., Zu, Y., Bhagat, G., Winter, J.N., Wang, H.Y., O'Neill, S., Dunphy, C.H., Hsi, E.D., Zhao, X.F., Go, R.S., Choi, W.W., Zhou, F., Czader, M., Tong, J., Zhao, X., van Krieken, J.H., Huang, Q., Ai, W., Etzell, J. & Ponzoni, M. (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia, 26, 2103-2113.
de Vos, S., Swinnen, L., Kozloff, M., Wang, D., Reid, E., Nastoupil, L., Fowler, N., Cordero, J., D’Amico, D., Diehl, S., Dunbar, M., Zhu, M., Wong, S., Enschede, S.H., Chien, D., Humerickhouse, R.A. & Flowers, C. (2015) A dose-escalation study of venetoclax (ABT-199/GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin’s lymphoma. Blood, 126, 255-255.
Wilson, W.H., Teruya-Feldstein, J., Fest, T., Harris, C., Steinberg, S.M., Jaffe, E.S. & Raffeld, M. (1997) Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin’s lymphomas. Blood, 89, 601-609.
Wilson, W.H., Grossbard, M.L., Pittaluga, S., Cole, D., Pearson, D., Drbohlav, N., Steinberg, S.M., Little, R.F., Janik, J., Gutierrez, M., Raffeld, M., Staudt, L., Cheson, B.D., Longo, D.L., Harris, N., Jaffe, E.S., Chabner, B.A., Wittes, R. & Balis, F. (2002) Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood, 99, 2685-2693.
Wilson, W.H., Dunleavy, K., Pittaluga, S., Hegde, U., Grant, N., Steinberg, S.M., Raffeld, M., Gutierrez, M., Chabner, B.A., Staudt, L., Jaffe, E.S. & Janik, J.E. (2008) Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. Journal of Clinical Oncology, 26, 2717-2724.
Wright, G., Tan, B., Rosenwald, A., Hurt, E.H., Wiestner, A. & Staudt, L.M. (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 100, 9991-9996.